Deep and Durable Response of Fixed-Duration Acalabrutinib in Combination with Venetoclax, +/- Obinutuzumab in Previously Untreated Adults with CLL
In this interview, Jennifer R. Brown, Dana-Farber Cancer Institute, Boston, gives her perspective on the AMPLIFY trial – the first randomized study to evaluate the efficacy and safety of fixed-duration acalabrutinib-venetoclax (±obinutuzumab). In the MEDtalk she explains the background and aim of the AMPLIFY trial and gives her opinion about the benefit of a fixed-duration treatment. Finally, Jennifer R. Brown evaluated the use of acalabrutinib in the future treatment of CLL.
Få tillgång
Om du är läkare, sjuksköterska eller annan vårdpersonal kan du komma åt hela artikeln genom att skapa en profil på BestPractice Nordic.
- Få tillgång
- Om du redan har en profil: Logga in